来源：36氪 今年中国创新药出海交易火热，其中，AI制药公司正成为一股不容小觑的力量。2025年3月至8月期间，元思生肽、华深智药海外子公司、晶泰科技等接 连完成总金额数十亿美金的BD交易。 其中，元思、华深成立仅四五年时间，便在跨国药企严格的BD挑选中取得成绩，正是通过AI改写了大分子药物研发范式、提高了研发成功率。这些交易 也给予了资本市场以信心，时隔三四年，数家AI制药公司近期重新拿到了融资。 | 披露时间 | 卖方 | 买方 | 首付款/近期付款 | 潜在里程碑 及销售分成等总额 | 平台(管线阶段) | | --- | --- | --- | --- | --- | --- | | 2025/8/5 | 晶泰科技 | DoveTree | 5100万美元 | 58.9亿美元 | 多款临床前/早期的大 分子与小分子创新药 资产 (DoveTree 指 | | | | | | | 定的多个靶点,晶泰 | | | | | | | 按约研发) | | 2025/6/13 | 石药集团 | 阿斯利康 | 1.1亿美元 | 53 亿美元 | 基于石药AI平台,共 同发现口服小分子候 选(多靶点、慢性/免 | | ...

Core Viewpoint - The article discusses the significant advancements in AI-driven drug discovery, highlighting a transformative shift in the pharmaceutical industry as AI technologies enable more precise and efficient drug design, moving from traditional methods to innovative approaches that can potentially revolutionize the sector [4][5][7]. Group 1: AI Drug Discovery Landscape - AI pharmaceutical companies are gaining traction, with several completing billion-dollar business development (BD) transactions, indicating renewed investor confidence in the sector [5][6]. - Notable transactions include a $5.1 billion deal between JingTai Technology and DoveTree, and a $1.1 billion collaboration between Shiyao Group and AstraZeneca, showcasing the financial potential of AI in drug development [6]. - The shift in drug discovery methodology is moving from empirical screening to rational design, allowing for the creation of novel drug candidates that were previously unattainable [5][9]. Group 2: Technological Advancements - The emergence of advanced AI models, such as AlphaFold 2, has significantly improved the understanding of protein structures, enabling the prediction of over 200 million protein structures in just two years [10]. - New models like Chai-2 and ESM3 are demonstrating enhanced capabilities in generating novel proteins and antibodies, achieving higher success rates in drug candidate identification compared to traditional methods [11][12]. - The ability of AI to design antibodies in a matter of hours, as opposed to the traditional three-year timeline, represents a paradigm shift in the drug development process [12]. Group 3: Industry Implications - The integration of AI in drug discovery is expected to shorten the preclinical development timeline, particularly benefiting areas like chronic disease treatment [13]. - AI-driven biotech firms are likely to become key players in drug design, while traditional pharmaceutical companies may focus more on clinical trials and commercialization [13][15]. - The competitive landscape is evolving, with three main types of players emerging: tech giants developing foundational models, startups optimizing existing models, and traditional firms leveraging AI for specific drug development [15][16]. Group 4: Future Outlook - The future of drug development will see all companies utilizing AI to varying degrees, emphasizing the importance of delivering viable drug candidates to achieve higher valuations [18]. - The ability to generate high-quality experimental data will be crucial for teams aiming to develop effective AI models, as data quality directly impacts model performance [17].

Core Insights - The US FDA has approved Wayrilz (rilzabrutinib) for adults with persistent or chronic immune thrombocytopenia (ITP) who have not responded adequately to previous treatments, based on the successful LUNA 3 phase 3 study [1][3] - Wayrilz is a novel oral Bruton's tyrosine kinase (BTK) inhibitor that targets multiple immune pathways to address the underlying causes of ITP [2][11] - The approval highlights Sanofi's commitment to developing innovative therapies for rare and immunological diseases [3][11] Study Results - The LUNA 3 study involved 202 adult patients and demonstrated that 64% of patients on Wayrilz achieved a platelet count response at 12 weeks compared to 32% in the placebo group [3][10] - Patients on Wayrilz reported a 10.6-point improvement in health-related quality of life measures, while the placebo group showed a 2.3-point increase [4] - Statistically significant results included a durable platelet response at week 25 (23% in Wayrilz vs. 0% in placebo; p<0.0001) and a faster time to first platelet response (36 days in Wayrilz vs. not reached in placebo; p<0.0001) [7] Treatment Implications - Wayrilz offers a new treatment option for patients who have not responded to steroids or existing therapies, potentially improving management of ITP [5][11] - The drug has received Fast Track and Orphan Drug Designations from the FDA for ITP and is under regulatory review in the EU and China [8][12] - Sanofi's HemAssist program will provide support for patients undergoing treatment with Wayrilz, including assistance with access and insurance coverage [9] Company Overview - Sanofi is an R&D driven biopharma company focused on innovative therapies for various diseases, including rare and immunological conditions [13] - The company is committed to leveraging its understanding of the immune system to develop effective treatments and improve patient outcomes [13]

炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 近日，天辰生物医药（苏州）股份有限公司（以下简称"天辰生物"）递表港交所，拟通过18A章规则上 市，国金证券（香港）为其独家保荐人。 资料显示，天辰生物成立于2020年10月，公司专注于针对过敏性及自身免疫性疾病的生物药物的自主发 现与开发，目前公司共有五款候选药物。其中，根据弗若斯特沙利文的资料，LP-003在全球下一代抗 IgE生物候选药物中的临床开发进度最快。 | | 直品 | 靶點/作用 提到 | 通用在 | ■床前/IND 事情 | 1期 | 川朝 | 111,5 | 主要監管 提携 | 權利 | 预计里程碑 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 最被性疾病 | LP-003 * | IgE | 李俯性AR | | | | | 國家華監局 | | III用臨床試驗完成:2026年上半年 提交BLA:2026年第三李度或之旨 | | | | | CSU | | | | | 國家康監局 | | II削臨床試驗完成:2026年上 ...

Group 1 - The "AD365 Atopic Dermatitis Education Project" is launched by the China Red Cross Foundation in collaboration with Sanofi, aiming to enhance public awareness of atopic dermatitis and promote standardized diagnosis and treatment [3] - The project will host a special patient education conference on September 1 at Taicang First People's Hospital, focusing on educating patients and their families about atopic dermatitis, its causes, and prevention strategies [1] - The theme of the event is "Building Healthy Skin Together, Embracing an Infinite Life," emphasizing the importance of community engagement and expert interaction for better disease management [1] Group 2 - The project officially started on May 15, 2025, and is part of the broader "Healthy China 2030" strategic goal, which aims to improve public health through systematic education [3] - The initiative involves collaboration with multiple medical institutions and experts to provide comprehensive knowledge about atopic dermatitis and its underlying mechanisms, particularly type 2 inflammation [1][3] - The event encourages participation from atopic dermatitis patients and their families to foster a better understanding of the condition and promote proactive health measures [1]

智通财经APP获悉，尽管法国政局再起波澜，但华尔街顶级机构认为这不足以动摇欧洲股市今年以来的强劲表现。法国总理贝鲁周一意外宣布就预算问题举 行信任投票，引发市场短暂震荡，法国CAC 40指数两日内一度下跌3.3%，法德10年期国债利差扩大至80个基点，创四月以来新高。不过高盛、花旗、摩根 大通等机构策略师指出，德国历史性财政改革与欧洲整体经济增长前景，有效对冲了法国政治风险的外溢效应。 今年欧洲股市表现堪称2006年以来最佳，斯托克600指数以美元计价跑赢标普500近13个百分点。尽管近期资金回流美国科技股导致指数未能突破三月高点， 但机构普遍看好欧洲基本面。 图1 花旗策略师Beata Manthey强调，当前欧洲资产价格已包含政治风险溢价，德国财政扩张与欧元走强构成核心支撑。高盛策略师Sharon Bell则认为，法国政局 动荡尚未对经济增长产生实质影响，市场对此早有预期。 奢侈品巨头路威酩轩、爱马仕、欧莱雅等CAC 40成分股在经历初期的抛售后迅速收复失地，显示国际化板块的韧性。数据显示，CAC 40成分股约80%收入 来自海外市场，赛诺菲、道达尔等跨国企业盈利受本土政治影响有限。 与此同时，欧元区8月 ...

Core Insights - The global vaccine market has been dominated by four major multinational pharmaceutical companies: Pfizer, MSD, GSK, and Sanofi, which have long led in sales and market share [2] - With the increasing global public health demand and rapid development of new technologies like mRNA vaccines, new opportunities and changes are emerging in the global vaccine market [2] - Chinese vaccine companies, represented by Watson Bio, are gradually emerging in the global market, leveraging advantages in R&D innovation, product quality, and cost control to challenge traditional giants [2] Globalization Strategy - In 2024, Watson Bio achieved remarkable results in overseas markets, with overseas revenue reaching approximately 570 million RMB, a significant year-on-year increase of 98.33%, accounting for about 20.21% of the company's total revenue [3] - The company has combined product sales with technology export, successfully seizing cooperation opportunities in countries along the "Belt and Road" initiative, and has established business cooperation discussions with over 80 clients in more than 30 countries [3][4] - Watson Bio's internationalization strategy has been a long-term effort, initiated over a decade ago, demonstrating deep market insights and strong execution [3][4] Challenges in Internationalization - Watson Bio faced challenges such as local material shortages, cultural differences, and regulatory discrepancies, which complicated the product registration process and increased the complexity of internationalization [4] - The company's successful international expansion provides valuable experience for other Chinese vaccine enterprises, proving that high-quality products can win reputation and that high cost-effectiveness and flexibility can meet diverse market needs [4] Transition from Product Export to Technology Export - Watson Bio is innovating its model by transitioning from simple product export to deeper technology transfer and localized production, which promotes mutual benefits and local vaccine industry upgrades [6] - Successful collaborations in Indonesia and Morocco for localized production of vaccines exemplify this model, indicating its replicability and adaptability to different countries [6] Role of Hong Kong as a Super Hub - Hong Kong plays a crucial role as a "super hub" in Watson Bio's globalization strategy, leveraging its unique advantages to facilitate international operations [7] - The city provides a robust international service system for technical certification, enhancing global trust in Chinese vaccines and facilitating market entry [7][8] - Hong Kong's financial and risk management advantages support Watson Bio's global operations, allowing for effective risk control and financial stability [7] Opportunities in Regulatory Innovation - Hong Kong is advancing the establishment of a "medicinal regulatory innovation cooperation demonstration zone," which aligns with the urgent needs of China's biopharmaceutical industry for internationalization [8] - The development of a "Hong Kong version of the FDA" aims to attract more innovative drug research and international clinical trials, integrating Chinese innovative medical technologies into the global industry chain [8]

Market Performance - The Hang Seng Index closed at 25,524, down 1.18% for the day but up 27.24% year-to-date [1] - The Hang Seng Tech Index closed at 5,782, down 0.74% for the day and up 29.41% year-to-date [1] - The Shanghai Composite Index closed at 3,868, down 0.39% for the day and up 15.41% year-to-date [1] - The Dow Jones Index closed at 45,418, up 0.30% for the day and up 6.75% year-to-date [1] Currency and Commodity Overview - The RMB Index is at 96.570, up 0.45% month-on-month but down 3.07% over six months [2] - Brent crude oil is priced at $68.020 per barrel, up 0.55% month-on-month but down 2.80% over six months [2] - Gold is priced at $3,377.33 per ounce, up 1.92% month-on-month and up 15.83% over six months [2] Company News - Nongfu Spring reported a net profit of 7.622 billion RMB for the first half of the year, an increase of 22.2% year-on-year, with revenue of 25.622 billion RMB, up 15.6% [14] - Yuexiu Property reported a net profit of 1.37 billion RMB for the first half of the year, a decrease of 25.2% year-on-year, with revenue of 47.574 billion RMB, up 34.6% [15] Economic Indicators - Hong Kong's exports in July increased by 14.3% year-on-year, marking the 17th consecutive month of growth [16][17] - The UK government faces pressure as bond yields approach a 27-year high, with the 30-year bond yield reaching 5.63% [18] IPO Information - Shuangdeng Co. debuted on August 26, 2025, with a closing price of 19.05, showing a cumulative performance increase of 31.29% [26] - Upcoming IPOs include Jiaxin International Resources, set to list on August 28, 2025, with a proposed price of 10.92 [26]

Core Viewpoint - The return of the original brand Mucosolvan (Ambroxol Hydrochloride) to the Chinese market is anticipated in December 2025, following its exit due to registration expiration and increased competition from generic drugs [1][2]. Group 1: Company Background - Mucosolvan was originally developed by Boehringer Ingelheim and launched in Germany in 1978, entering the Chinese market in 1991 [2]. - The product achieved peak sales exceeding 8 billion yuan in China, making it a highly competitive product in the market [2]. - The original manufacturer, Boehringer Ingelheim, ceased the product's registration in China in 2020, leading to its market exit [3]. Group 2: Market Competition - The return of Mucosolvan will face competition from 367 similar drug approvals in China, including significant price competition from generics [6]. - In the 2021 centralized procurement, Boehringer Ingelheim's bid was only a 0.3% price reduction, while competitors like Yunnan Longhai offered a 93.3% reduction [4]. - The market for expectorants is crowded, with other active ingredients available, such as bromhexine and acetylcysteine, which may affect Mucosolvan's market share [6]. Group 3: Future Outlook - The product's return is now under the management of Opella, a company that became independent from Sanofi in May 2025, which retains a 48.2% stake in Opella [4]. - The ability of Mucosolvan to regain consumer trust and willingness to pay a premium in a low-price environment remains uncertain [6]. - The performance of Mucosolvan post-return will be closely monitored, especially regarding its positioning in the OTC market [6].

经济观察网 据智通财经援引外媒报道，美国总统特朗普在当地时间8月25日的简报会上表示，他将把美 国药品价格下调1400%至1500%，还将对美国的药品成本进行一些研究。同时，特朗普重申考虑对进口 药品征收高达250%的关税。 上述表态被视为强调了特朗普政府对药品定价的激进立场。受此影响，美股医药板块8月25日普跌。辉 瑞（PFE）跌2.86%，赛诺菲安万特（SNY）跌2.38%，默沙东（MRK）跌2.36%，礼来（LLY）收跌 2.3%，百时美施贵宝（BMY）跌1.63%，阿斯利康（AZN）跌1.62%，葛兰素史克（GSK）跌1.37%， 诺华（NVS）跌1.53%，强生（JNJ）跌0.49%。 ...